Skip to main content

Advertisement

SpringerLink
Log in

Gelatinase Activity of Matrix Metalloproteinases During First-Line Chemotherapy in Lung Adenocarcinoma Patients: An Initial Approach

  • Published:
Lung Aims and scope Submit manuscript

Abstract

Background

The aim of this study was to determine if gelatinase activity of plasma matrix metalloproteinases (MMPs) can be used as a method to assess chemotherapy response and cancer progression in primary lung adenocarcinoma patients.

Methods

A group of 28 patients was divided according to risk factor as follows: lung cancer associated with wood smoke exposure (LCW), lung cancer in tobacco smokers (LCT), and patients with no association to a known risk factor (LCN). Plasma gelatinase activity was measured by zymography and radiolabeled gelatin degradation.

Results

The chemotherapy response was better in the LCW group (25%) compared with the LCT (7.1%) patients (P = 0.039). MMP gelatinase activity was increased in all lung cancer subjects. Patients with progression of the disease had a significant increase in gelatinase activity compared with subjects, with a response to treatment (330.3 ± 44.4 and 64.9 ± 8.5 μg of degraded gelatin/mg of incubated plasma protein, respectively, P = 2.972 × 10−5). Zymography assay revealed that the increase in gelatinase activity corresponded mainly to MMP-2.

Conclusions

Patients with progression of lung adenocarcinoma, mainly from the LCT group, had an increase in gelatinase activity compared with subjects that responded to chemotherapy. Therefore, plasma gelatinase activity, particularly MMP-2 enzymatic activity, could be used as a way to assess lung adenocarcinoma progression as well as an indicator for the use of MMP-2 inhibitors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Toh CK (2009) The changing epidemiology of lung cancer. Methods Mol Biol 472:397–411

    Article  PubMed  Google Scholar 

  2. Scagliotti GV, Longo M, Novello S (2009) Non small cell lung cancer in never smokers. Curr Opin Oncol 21:99–104

    Article  PubMed  CAS  Google Scholar 

  3. Delgado J, Martínez LM, Sánches TT et al (2005) Lung cancer pathogenesis associated with wood smoke exposure. Chest 128:124–131

    Article  PubMed  CAS  Google Scholar 

  4. Straif K, Baan R, Grosse Y, Secretan B, Ghissassi FE, Cogliano V, WHO International Agency for Research on Cancer Monograph Working Group (2006) Carcinogenicity of household solid fuel combustion and of high-temperature frying. Lancet Oncol 7:977–978

    Article  PubMed  Google Scholar 

  5. Torres-Duque C, Maldonado D, Perez-Padilla R, FIRS Task Force on Health Effects of Biomass Exposure et al (2008) Biomass fuels and respiratory diseases. Proc Am Thorac Soc 5:1–14

    Article  Google Scholar 

  6. Visse R, Nagase H (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases. Structure, function and biochemistry. Circ Res 92:827–839

    Article  PubMed  CAS  Google Scholar 

  7. Baker AH, Edwards DR, Murphy G (2002) Metalloproteinases inhibitors: biological actions and therapeutic opportunities. J Cell Sci 115:3719–3727

    Article  PubMed  CAS  Google Scholar 

  8. Deyugina EI, Quigley JP (2006) Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 25:9–34

    Article  Google Scholar 

  9. Duffy M, McGowan PM, Gallager WM (2008) Cancer invasion and metastasis: changing views. J Pathol 214:283–293

    Article  PubMed  CAS  Google Scholar 

  10. Mountain CF (1997) Revisions in the international system for staging lung cancer. Chest 111:1710–1717

    Article  PubMed  CAS  Google Scholar 

  11. Adizzoni A, Boni L, Tiseo M et al (2007) Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: An individual patient data meta-analysis. J Natl Cancer Inst 99:847–857

    Article  Google Scholar 

  12. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216

    Article  PubMed  CAS  Google Scholar 

  13. Smith PK, Krohn RI, Hermanson GT et al (1985) Measurement of protein using bicinchoninic acid. Anal Biochem 150:76–85

    Article  PubMed  CAS  Google Scholar 

  14. Sunada H, Nagai Y (1980) A rapid microassay method for gelatinolytic activity using tritium-labeled heat-denatured polymeric collagen as a substrate and its application to the detection of enzymes involved in collagen metabolism. J Biochem 87:1765–1772

    PubMed  CAS  Google Scholar 

  15. Vadillo-Ortega F, Gonzalez-Avila G, Furth EE et al (1995) 92 kD type IV collagenase (matrix metalloproteinase-9) activity in human amniochorion increases with labor. Am J Pathol 146:148–156

    PubMed  CAS  Google Scholar 

  16. Garbisa S, Sagliotti G, Masiero L et al (1992) Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy. Cancer Res 52:4548–4549

    PubMed  CAS  Google Scholar 

  17. Reckamp KL, Gardner BK, Figlin RA et al (2008) Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum soluble E-cadherin. J Thorac Oncol 3:117–124

    Article  PubMed  Google Scholar 

  18. Hrabec E, Strek M, Nowk D et al (2001) Elevated level of circulating matrix metalloproteinase-9 in patients with lung cancer. Respir Med 95:1–4

    Article  PubMed  CAS  Google Scholar 

  19. Bayramoglu A, Gunes HV, Metintas M et al (2009) The association of MMP-9 enzyme activity, MMP-9 C1562T polymorphism and MMP-2 and MMP-9 and TIMP-1, -2, -3 and -4 gene expression in lung cancer. Genet Test Mol Biomarkers 13:671–678

    Article  PubMed  CAS  Google Scholar 

  20. Inesta P, Moran A, De Juan C et al (2007) Biological and clinical significance of MMP-2, MMP-9, TIMP-1 and TIMP-2 in non-small cell lung cancer. Oncol Rep 17:217–223

    Google Scholar 

  21. Iijima T, Minami Y, Nakamura N et al (2004) MMP-2 activation and stepwise progression of pulmonary adenocarcinoma: analysis of MMP-2 and MMP-9 with gelatin zymography. Pathol Int 54:295–301

    Article  PubMed  CAS  Google Scholar 

  22. Amalinei C, Caruntu ID, Giusca SE et al (2010) Matrix metalloproteinases involvement in pathologic conditions. Rom J Morphol Embryol 51:215–228

    PubMed  Google Scholar 

  23. Skipper JB, McNally LR, Rosenthal EL et al (2009) In vivo efficacy of marimastat and chemoradiation in head and neck cancer xenografts. ORL J Otorhinolaryngol Relat Spec 71:1–5

    Article  PubMed  CAS  Google Scholar 

  24. Chetty C, Bhoopathi P, Joseph P et al (2006) Adenovirus-mediated small interfering RNA against matrix metalloproteinase-2 suppresses tumor growth and lung metastasis in mice. Mol Cancer Ther 5:2289–2299

    Article  PubMed  CAS  Google Scholar 

  25. Veiseh O, Gunn JW, Kievit F et al (2009) Inhibition of tumor cell invasion with chlorotoxin-bound superparamagnetic nanoparticles. Small 5:256–264

    Article  PubMed  CAS  Google Scholar 

  26. Badiga AV, Chetty C, Kesanakurti D et al (2011) MMP-2 siRNA inhibits radiation-enhanced invasiveness in glioma cells. PLoS One 6:e20614

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study was supported by a grant from CONACYT (SALUD-2003-C01-8).

Disclosure

The authors have no conflicts of interest to declare.

Author information

Authors and Affiliations

  1. Biomedical Oncology Laboratory, Department of Chronic Degenerative Diseases, Instituto Nacional de Enfermedades Respiratorias, Mexico City, México

    Georgina Gonzalez-Avila, Bettina Sommer, Javier Delgado, Arnoldo Aquino-Galvez & Carlos Ramos

  2. Service of Oncology, Instituto Nacional de Enfermedades Respiratórias, Mexico City, México

    Daniel A. Mendoza-Posada

  3. Laboratorio de Oncología Biomédica, Departamento de Enfermedades Crónico Degenerativas, Instituto Nacional de Enfermedades Respiratorias, Calzada de Tlalpan 4502, CP 14080, México, DF, México

    Georgina Gonzalez-Avila

Authors
  1. Georgina Gonzalez-Avila
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bettina Sommer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daniel A. Mendoza-Posada
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Javier Delgado
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Arnoldo Aquino-Galvez
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Carlos Ramos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Georgina Gonzalez-Avila.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gonzalez-Avila, G., Sommer, B., Mendoza-Posada, D.A. et al. Gelatinase Activity of Matrix Metalloproteinases During First-Line Chemotherapy in Lung Adenocarcinoma Patients: An Initial Approach. Lung 190, 99–104 (2012). https://doi.org/10.1007/s00408-011-9336-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00408-011-9336-x

Keywords

Search

Navigation